Persistence of high sustained antibodies to enzyme replacement therapy despite extensive immunomodulatory therapy in an infant with Pompe disease: Need for agents to target antibody-secreting plasma cells
- 1 April 2012
- journal article
- case report
- Published by Elsevier in Molecular Genetics and Metabolism
- Vol. 105 (4) , 677-680
Abstract
No abstract availableKeywords
This publication has 21 references indexed in Scilit:
- Enzyme replacement therapy induces T-cell responses in late-onset Pompe diseaseMuscle & Nerve, 2011
- The impact of antibodies on clinical outcomes in diseases treated with therapeutic protein: Lessons learned from infantile Pompe diseaseGenetics in Medicine, 2011
- Cross-reactive immunologic material status affects treatment outcomes in Pompe disease infantsMolecular Genetics and Metabolism, 2010
- Early Treatment With Alglucosidase Alfa Prolongs Long-Term Survival of Infants With Pompe DiseasePediatric Research, 2009
- Biochemical and pharmacological characterization of different recombinant acid α-glucosidase preparations evaluated for the treatment of Pompe diseaseMolecular Genetics and Metabolism, 2008
- Immune tolerance induction to enzyme-replacement therapy by co-administration of short-term, low-dose methotrexate in a murine Pompe disease modelClinical and Experimental Immunology, 2008
- Nephrotic Syndrome Complicating α-Glucosidase Replacement Therapy for Pompe DiseasePediatrics, 2004
- The Natural Course of Infantile Pompe’s Disease: 20 Original Cases Compared With 133 Cases From the LiteraturePediatrics, 2003
- Management of Neutralizing Antibody to Ceredase in a Patient With Type 3 Gaucher DiseasePediatrics, 1997
- Induction of Immune Tolerance in Patients with Hemophilia and Antibodies to Factor VIII by Combined Treatment with Intravenous IgG, Cyclophosphamide, and Factor VIIINew England Journal of Medicine, 1988